Although the combination of amivantamab and chemotherapy has become a new standard of care as second-line treatment for patients with advanced-stage EGFR-mutant NSCLC, this regimen also carries high rates of AEs, with 58% of patients reporting infusion-related reaction (all-grades), and 72% of patients had grade 3 or greater events.28 Here, EGFR is linked to non-small cell lung carcinoma.